News

The FDA approvals covered biologics license application (BLA) submissions for 26 monoclonal antibody based blood grouping reagents, two anti-human globulin products, 13 reagent red blood cell products and

For the past 11 years, Ms Santis served as director of investor relations and corporate communications at Human Genome Sciences. Ms Santis holds an MBA in marketing management

Ralivia is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. The new indication is

Mr Smith will oversee the US Oncology research network, which provides research management services to oncology practices and sites throughout the nationwide US oncology network. Mr Smith joins

Mr Stevens’s professional background includes leadership positions at architectural and engineering design firm, HNTB Company and Fidelity Investments. Additional leadership roles held within the medical industry feature corporations

This open-label, sequential dose escalation study will be conducted at cancer institutions in Europe and will evaluate AV-951 in combination with the Folfox6 chemotherapy regimen in patients with

The terms of the deal call for payment of a non-refundable, up-front licensing fee and further payment of an additional non-refundable license fee upon procurement of the requisite

The Phase III chronic lymphocytic leukemia (CLL) front line chlorambucil combination study is an open-label, parallel-arm study that will include 444 patients with previously untreated CLL. Patients in

The Asia-Pacific Innovation Center is now the home base for new Hill-Rom teams focused on R&D projects for global applications of various Hill-Rom products. The Singapore Center is